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ABSTRACT
Objective To assess the safety and efﬁcacy of
ixekizumab, a monoclonal antibody that inhibits
interleukin-17A, in a double-blind phase III trial enrolling
patients with active psoriatic arthritis (PsA).
Methods Patients naive to biologic therapy with active
PsA were randomised to subcutaneous injections of
placebo (N=106), adalimumab 40 mg once every 2 weeks
(active reference; N=101), ixekizumab 80 mg once every
2 weeks (IXEQ2W) (N=103), or ixekizumab 80 mg once
every 4 weeks (IXEQ4W) (N=107). Both ixekizumab
regimens included a 160-mg starting dose. The primary
objective was to assess the superiority of IXEQ2W or
IXEQ4W versus placebo as measured by the proportion of
patients achieving an American College of Rheumatology
20 (ACR20) response at week 24.
Results Signiﬁcantly more patients treated with
ixekizumab achieved an ACR20 response with IXEQ2W
(62.1%) or IXEQ4W (57.9%) than placebo (30.2%)
(p≤0.001; non-responder imputation method). Disease
activity and functional disability were signiﬁcantly
improved with both ixekizumab doses versus placebo at
weeks 12 and 24, and there was signiﬁcantly less
progression of structural damage at week 24 (p≤0.01).
Clearance of plaque psoriasis was greater with ixekizumab
than placebo (p≤0.001). Efﬁcacy results with
adalimumab, the active reference arm, showed signiﬁcant
improvements versus placebo. Treatment-emergent
adverse events were more frequent with ixekizumab
(65.7–66.4%) and adalimumab (64.4%) than placebo
(47.2%) (p<0.05).
Conclusions In biologic-naive patients with active PsA,
ixekizumab treatment resulted in improvements in disease
activity and physical function, as well as in the inhibition of
structural damage progression. Overall, adverse events were
more frequent in all active groups compared with placebo.
Trial registration number NCT01695239;
EudraCT2011-002326-49; Results.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic,
immune-mediated, inﬂammatory arthritis
commonly associated with plaque psoriasis, joint
damage, dactylitis, enthesitis and axial involve-
ment.1 2 PsA can be progressive and destructive,
resulting in physical deformities, impaired function,
decreased quality of life and increased mortality.3 4
The cytokine interleukin (IL)-17A promotes joint
inﬂammation and damage by triggering the activa-
tion and trafﬁcking of immune cells, inducing
proinﬂammatory cytokines and chemokines, acting
as a chemoattractant to neutrophils and monocytes,
and stimulating release of matrix metalloproteases
and receptor activator of nuclear factor kappa-B
ligand, which contribute to cartilage and bone
destruction, respectively.5 Increased numbers of
IL-17A-producing cells are present in the periph-
eral blood, synovial tissue and ﬂuid, and skin
plaques of patients with PsA;6–11 the concentration
of IL-17A-producing cells correlates with disease
activity.10 Based on these ﬁndings, speciﬁc inhib-
ition of IL-17A represents an emerging targeted
approach to PsA management.12 13
Ixekizumab, a recombinant, high-afﬁnity, huma-
nised, immunoglobulin G4κ monoclonal antibody
selectively binds and neutralises IL-17A. The safety
and efﬁcacy of ixekizumab in patients with active
PsA not previously treated with biologic agents are
under investigation in a phase III study (SPIRIT-
P1). Here we report the results from the 24-week,
placebo-controlled and active-controlled, double-
blind period of this study.
METHODS
Study design and patient population
The SPIRIT-P1 study (NCT01695239, EudraCT
2011-002326-49) is a 3-year, phase III, rando-
mised, double-blind, placebo-controlled and active-
controlled clinical trial comparing two regimens of
ixekizumab and an active reference arm adalimu-
mab (Humira; AbbVie) at the approved dose and
regimen to treatment with placebo in patients not
previously treated with biologic agents for plaque
psoriasis or PsA. The double blind period of the
study occurred in the ﬁrst 24 weeks. Enrolled
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patients fulﬁlled the Classiﬁcation Criteria for Psoriatic Arthritis
(CASPAR);14 had ≥3 of 68 tender joint count and ≥3 of 66
swollen joint count; and had either ≥1 PsA-related hand or foot
joint erosion on centrally read X-rays or C reactive protein
>6 mg/L. Further discussion of study design and patient popula-
tion is included in the online supplementary material.
Treatment and randomisation
Randomisation was performed centrally via an interactive voice
response system based on a computer-generated randomisation
code, with stratiﬁcation by country and by prior/current/no
use of conventional (non-biologic) disease-modifying antirheu-
matic drugs (cDMARDs). Patients were randomised at a 1:1:1:1
ratio to one of four treatment groups: ixekizumab 80 mg every 2
weeks (IXEQ2W), ixekizumab 80 mg every 4 weeks (IXEQ4W),
adalimumab 40 mg Q2W, or placebo, all administered via sub-
cutaneous injection (see online supplementary ﬁgure S1). Patients
randomised to IXEQ4Wor IXEQ2W were administered a start-
ing dose of 160 mg given as two injections at week 0. Because
the different randomised treatments used distinct schedules and
distinguishable preﬁlled syringes, a double-dummy design with
Q2W dosing was employed to conceal treatment allocation (see
online supplementary ﬁgure S2).
Patients in all treatment groups with an inadequate response
at week 16, distinguished by predeﬁned tender and swollen
joint count criteria (Inadequate Responders), were required to
add or modify concomitant medications. The investigators,
study personnel and patients were blinded to the Inadequate
Response criteria. The Inadequate Response criteria are being
applied in another ongoing and currently blinded study
(SPIRIT-P2) in bDMARD-experienced patients with active PsA
and thus, must remain blinded. Inadequate Responders
remained on their originally assigned dose of ixekizumab or, if
receiving adalimumab or placebo, were randomised again to
IXEQ2W or IXEQ4W in a 1:1 ratio (see online supplementary
ﬁgure S1). Inadequate Responders from the adalimumab treat-
ment group received 8 weeks of placebo as a washout therapy
prior to initiating ixekizumab treatment at week 24.
Patients already on stable doses of allowed cDMARDs, oral
corticosteroids, opiates and/or non-steroidal anti-inﬂammatory
drugs/cyclo-oxygenase-2 inhibitors continued these on study.
Further discussion of treatment, concomitant medications and
randomisation is provided in the online supplementary material.
Study assessments
On scheduled study visits (weeks 1, 2, 4, 8, 12, 16, 20 and 24)
during the double-blind treatment period, patients underwent
assessments for safety and efﬁcacy end points and were supplied
with study medication if scheduled. Radiographic images of the
hands and feet taken at the screening visit, week 16 and week
24 were assessed centrally by two expert readers who were
blinded to treatment allocation, time point and patient data.
The primary efﬁcacy end point was the proportion of patients
achieving an American College of Rheumatology (ACR) 20
response at week 24 versus placebo. Deﬁnitions of the ACR20,
ACR50 and ACR70 responses used in the study are provided in
the online supplementary material.15
Secondary end points included the proportion of patients
achieving ACR50 or ACR70 responses; the proportion of
patients achieving a 75%, 90% or 100% improvement in
Psoriasis Area and Severity Index score (PASI 75, PASI 90 and
PASI 100, respectively);16 17 percentage of psoriasis-affected
body surface area (BSA); change from baseline in the Health
Assessment Questionnaire-Disability Index (HAQ-DI);18 19
change from baseline in the van der Heijde modiﬁed total Sharp
score (mTSS, a measure of structural disease progression based
on radiographic assessment of bone erosions and joint space
narrowing in the hands and feet);20 and change from baseline in
28-joint Disease Activity Score using C reactive protein
(DAS28-CRP) versus placebo.21 Additional secondary end
points for patients affected at baseline were enthesitis (inﬂam-
mation of tendon and ligament insertions, as assessed by the
presence or absence of tenderness at the six sites of the Leeds
Enthesitis Index (LEI)),22 dactylitis (swelling of the whole digit,
with assessment of the number of all 20 digits that are affected,
according to the Leeds Dactylitis Index-Basic (LDI-B)),23 24 the
Itch Numeric Rating Scale (itch NRS)25 and a modiﬁed version
of the Nail Psoriasis Severity Index (NAPSI),26 which assessed
ﬁngernails only.
Safety evaluations included adverse event (AE) reporting, vital
signs, physical exam ﬁndings, concomitant medications, ECG,
and drug immunogenicity, haematology and laboratory evalua-
tions. AEs of special interest included cytopenias, liver function
test changes/enzyme elevations, infections, injection site reactions,
hypersensitivity, cerebrocardiovascular events, malignancies,
Pneumocystis pneumonia/interstitial lung disease, depression and
Crohn’s disease/ulcerative colitis.
Statistical analyses
Efﬁcacy analyses were conducted on the intent-to-treat popula-
tion (all randomised patients). Primary analyses of categorical
variables were based on a logistic regression analysis with treat-
ment, geographical region and baseline cDMARD experience in
the model. Missing data were imputed using a non-responder
imputation method, in which patients who were Inadequate
Responders, or who discontinued treatment before week 24,
were deﬁned as non-responders. The primary analyses for all
continuous variables were based on mixed-effects models for
repeated measures with treatment, geographical region, baseline
score, baseline cDMARD experience, visit and the interaction of
treatment-by-visit in the model. To control the overall type I
error rate at a two-sided α level of 0.05, a multiplicity-
controlled analysis was used for the primary end point and the
six predetermined secondary end points. If the week 24 ACR20
primary efﬁcacy analysis was signiﬁcant for one or both ixekizu-
mab doses, the secondary analyses were considered in the fol-
lowing sequence: week 24 HAQ-DI, week 24 mTSS, week 12
ACR20, week 12 PASI 75, week 12 LEI and week 12 itch NRS.
All other secondary end points were assessed at a signiﬁcance
level of p<0.05 with no adjustment for multiplicity. Safety ana-
lyses were conducted on the safety population (all patients who
took at least one dose of study medication). Fisher’s exact test
was used for categorical safety data. Continuous safety variables
used analysis of covariance (ANCOVA) with treatment and base-
line value in the model. Details of additional statistical methods
are provided in the online supplementary material.
The adalimumab 40 mg Q2W treatment arm served as active
reference for comparison with placebo. The study was not
powered to test equivalence or non-inferiority of ixekizumab
versus adalimumab.
RESULTS
Patient population
Of 719 patients screened, 417 were randomised (see online
supplementary ﬁgure S3). The mean age was 49.5 years, 46.0%
were male, 85.3% were cDMARD-experienced, 64% were cur-
rently using cDMARDs and 54.2% reported current methotrex-
ate use. For those taking methotrexate at baseline, the average
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methotrexate dose was 15.8±5.04 mg/week (mean±SD).
Overall, 69.5% had psoriasis involving ≥3% of BSA, 58% had
enthesitis and 37.6% had dactylitis at baseline (table 1).
Of the 382 patients completing the 24-week double-blind
period, 57 were Inadequate Responders (11 IXEQ4W, 10
IXEQ2W, 9 adalimumab, 27 placebo) and received rescue medi-
cation from week 16 through week 24. A numerically greater
percentage of patients in the IXEQ4W (90.7%), IXEQ2W
(94.2%) and adalimumab (96%) groups than in the placebo
group (85.8%) completed the 24 weeks.
Table 1 Baseline characteristics of the patients according to treatment group
Placebo IXEQ4W IXEQ2W Adalimumab 40 mg Q2W* Total
N=106 N=107 N=103 N=101 N=417
Age (years), mean (SD) 50.6 (12.3) 49.1 (10.1) 49.8 (12.6) 48.6 (12.4) 49.5 (11.9)
Male, n (%) 48 (45.3) 45 (42.1) 48 (46.6) 51 (50.5) 192 (46.0)
Weight (kg), mean (SD) 83.8 (19.6) 85.5 (23.0) 81.6 (17.5) 91.6 (21.9)† 85.6 (20.9)
BMI (kg/m2), mean (SD) 29.2 (6.3) 30.2 (8.4) 28.6 (6.6) 32.1 (11.4)‡ 30 (8.5)
Race, n (%)
White 99 (93.4) 102 (95.3) 96 (93.2) 95 (94.1) 392 (94.0)
Asian 5 (4.7) 2 (1.9) 5 (4.9) 3 (3.0) 15 (3.6)
American Indian or Alaska native 2 (1.9) 2 (1.9) 2 (1.9) 3 (3.0) 9 (2.2)
Other 0 1 (0.9) 0 0 1 (0.2)
Time since psoriatic arthritis diagnosis (years), mean (SD) 6.3 (6.9) 6.2 (6.4) 7.2 (8.0) 6.9 (7.5) 6.7 (7.2)
Time since psoriasis diagnosis (years), mean (SD) 16.0 (13.8) 16.5 (13.8) 17.0 (14.0) 15.7 (12.7) 16.3 (13.5)
Background cDMARD therapy, n (%)
Naïve 13 (12.3) 17 (15.9) 17 (16.5) 14 (13.9) 61 (14.6)
Past use 24 (22.6) 22 (20.6) 23 (22.3) 20 (19.8) 89 (21.3)
Current use 69 (65.1) 68 (63.6) 63 (61.2) 67 (66.3) 267 (64.0)
Methotrexate current use, n (%) 59 (55.7) 57 (53.3) 53 (51.5) 57 (56.4) 226 (54.2)
Patients with specific disease characteristics, n (%)
Current psoriasis§ 102 (96.2) 100 (93.5) 95 (92.2) 97 (96.0) 394 (94.5)
Psoriasis BSA ≥3%¶ 67 (67.7) 73 (73.0) 59 (64.8) 68 (72.3) 267 (69.5)
Fingernail psoriasis§ 74 (69.8) 70 (65.4) 74 (71.8) 71 (70.3) 289 (69.3)
Dactylitis§ 39 (36.8) 54 (50.5) 41 (39.8) 23 (22.8)‡ 157 (37.6)
Enthesitis§ 57 (53.8) 70 (65.4) 59 (57.3) 56 (55.4) 242 (58.0)
Baseline disease and quality of life scores, mean (SD)
Tender joint count (68 joints) 19.2 (13.0) 20.5 (13.7) 21.5 (14.1) 19.3 (13.0) 20.1 (13.4)
Swollen joint count (66 joints) 10.6 (7.3) 11.4 (8.2) 12.1 (7.2) 9.9 (6.5) 11.0 (7.4)
HAQ-DI 1.2 (0.60) 1.2 (0.54) 1.2 (0.57) 1.1 (0.59) 1.2 (0.58)
Patient-reported pain VAS 0–100 58.5 (23.0) 60.1 (19.4) 58.4 (21.7) 58.7 (19.7) 58.9 (20.9)
Patient-assessed global disease activity VAS 0–100 61.1 (22.7) 62.7 (19.1) 62.5 (19.9) 59.1 (19.1) 61.4 (20.2)
Physician-assessed global disease activity VAS 0–100 55.9 (19.3) 57.6 (18.7) 58.5 (19.0) 55.4 (18.7) 56.9 (18.9)
CRP (mg/L) 15.1 (23.6) 12.8 (16.4) 15.1 (25.9) 13.2 (19.1) 14.1 (21.5)
mTSS 17.6 (28.6) 19.2 (32.7) 15.2 (28.9) 15.9 (27.4) 17.0 (29.4)
DAS28-CRP 4.9 (1.0) 5.0 (1.0) 5.0 (1.1) 4.9 (1.0) 4.9 (1.0)
LEI** 2.9 (1.7) 2.7 (1.6) 3.1 (1.8) 3.0 (1.6) 2.9 (1.7)
LDI-B†† 46.2 (65.5) 58.1 (96.7) 40.6 (54.6) 93.9 (111.9)‡ 55.8 (83.6)
LDI-B‡‡ 62.7 (69.3) 73.0 (103.4) 64.0 (56.6) 119.9 (113.5)‡ 75.9 (89.4)
% Psoriasis BSA involved¶ 14.4 (20.2) 15.1 (16.3) 12.0 (15.6) 14.8 (19.2) 14.1 (17.9)
PASI total score¶ 6.2 (7.5) 6.9 (6.6) 6.0 (7.0) 5.5 (6.5) 6.1 (6.9)
NAPSI§§ 19.8 (17.2) 21.3 (18.9) 25.0 (21.2) 20.9 (17.5) 21.8 (18.8)
SF-36 PCS 34.0 (8.3) 32.4 (10.1) 34.2 (8.7) 33.9 (8.8) 33.6 (9.0)
*The adalimumab 40 mg Q2W treatment arm served as active reference for comparison with placebo. The study was not powered to test equivalence or non-inferiority of ixekizumab
versus adalimumab.
†p≤0.01 vs placebo.
‡p<0.05 vs placebo.
§Presence or absence, as qualitatively assessed by the investigator.
¶Evaluated in patients with psoriasis, as qualitatively assessed by the investigator, at baseline.
**Evaluated in patients with enthesitis, as qualitatively assessed by the investigator, at baseline.
††Evaluated in patients with dactylitis, as qualitatively assessed by the investigator, at baseline.
‡‡Evaluated in patients with baseline LDI-B score >0; post hoc analysis.
§§Evaluated in patients with fingernail psoriasis, as qualitatively assessed by the investigator, at baseline.
BMI, body mass index; BSA, body surface area; cDMARD, conventional disease-modifying antirheumatic drug; CRP, C reactive protein; DAS28-CRP, 28-joint Disease Activity Score using C
reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; LDI-B, Leeds
Dactylitis Index-Basic; LEI, Leeds Enthesitis Index; mTSS, van der Heijde modified total Sharp score; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; Q2W,
every 2 weeks; SF-36 PCS, Short Form (36 Items) Health Survey Physical Component Score; VAS, visual analogue scale.
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Efﬁcacy results
Table 2 summarises the outcomes of efﬁcacy end points at 12
weeks and 24 weeks. The primary efﬁcacy end point of ACR20
response at week 24 was met with both IXEQ4W (57.9%) and
IXEQ2W (62.1%); response rates in both ixekizumab groups
were signiﬁcantly greater than in the placebo group (30.2%)
(p≤0.001) (ﬁgure 1A). The adalimumab group (active reference)
also had a signiﬁcantly greater ACR20 response at week 24
(57.4%) compared with placebo (p≤0.001). Despite the adali-
mumab group having a statistically higher baseline weight and
Table 2 Comparison of efficacy during the 24 weeks of placebo-controlled therapy
Placebo IXEQ4W IXEQ2W Adalimumab 40 mg Q2W*
12 weeks 24 weeks 12 weeks 24 weeks 12 weeks 24 weeks 12 weeks 24 weeks
Responder rate:
N=106 N=107 N=103 N=101
ACR20, % 31.1 30.2 57.0† 57.9† 60.2† 62.1† 51.5‡ 57.4†
ACR50, % 4.7 15.1 33.6† 40.2† 39.8† 46.6† 29.7† 38.6†
ACR70, % 0 5.7 15.0 23.4† 16.5 34.0† 17.8 25.7†
N=92 N=100 N=90 N=89
HAQ-DI MCID, %§ 29.3 26.1 49.0‡ 49.0† 64.4† 57.8† 49.4‡ 49.4†
N=28 N=39 N=26 N=18
LDI-B (0), %¶,** 53.6 25.0 74.4 79.5† 69.2 76.9† 61.1 77.8†
N=57 N=68 N=57 N=54
LEI (0), %¶,†† 28.1 19.3 27.9 42.6‡ 47.4‡‡ 38.6§§ 35.2 33.3
N=67 N=73 N=59 N=68
PASI 75, %¶¶ 7.5 10.4 75.3† 71.2† 69.5† 79.7† 33.8† 54.4†
PASI 90, %¶¶ 1.5 6.0 52.1† 56.2† 57.6† 67.8† 22.1‡ 36.8†
PASI 100, %¶¶ 1.5 3.0 31.5† 42.5† 40.7† 52.5† 14.7§§ 23.5‡
N=41 N=52 N=41 N=37
sPGA (0, 1), %*** 7.3 17.1 75.0† 65.4† 80.5† 73.2† 45.9† 62.2†
sPGA (0), %*** 2.4 2.4 30.8‡ 38.5‡ 36.6‡ 39.0‡ 10.8 18.9‡‡
N=74 N=70 N=74 N=71
NAPSI (0), %††† 8.1 18.9 20.0‡‡ 25.7 27.0‡ 36.5§§ 19.7‡‡ 39.4‡
LS mean change from baseline (SE):
N=106 N=107 N=103 N=101
DAS28-CRP −0.57 (0.11) −0.84 (0.13) −1.63 (0.11)† −1.96 (0.12)† −1.67 (0.11)† −2.04 (0.12)† −1.57 (0.12)† −1.74 (0.12)†
N=106 N=107 N=103 N=101
HAQ-DI −0.13 (0.05) −0.18 (0.05) −0.37 (0.05)† −0.44 (0.05)† −0.47 (0.05)† −0.50 (0.05)† −0.35 (0.05)† −0.37 (0.05)‡
N=106 N=107 N=103 N=101
SF-36 PCS 2.3 (0.8) 2.9 (1.0) 5.8 (0.8)† 7.5 (0.9)† 7.6 (0.8)† 8.2 (0.9)† 5.7 (0.8)† 6.8 (0.9)‡
N=28 N=39 N=26 N=18
LDI-B¶,** −36.3 (10.3) −33.7 (9.7) −72.8 (8.8) † −75.4 (8.1)† −63.9 (10.6)‡‡ −66.1 (9.8)‡ −62.1 (11.9) −76.0 (10.9)†
N=57 N=70 N=59 N=56
LEI‡‡‡ −0.8 (0.24) −0.8 (0.26) −0.9 (0.21) −1.3 (0.21) −1.5 (0.24)‡‡ −1.4 (0.24) −0.8 (0.24) −0.9 (0.23)
N=102 N=100 N=95 N=97
% BSA§§§ −1.6 (1.2) −2.7 (1.4) −10.4 (1.2)† −12.0 (1.3)† −8.8 (1.2)† −10.6 (1.4)† −7.7 (1.2)† −9.5 (1.4)†
N=74 N=70 N=74 N=71
NAPSI††† −1.1 (1.4) −2.4 (1.7) −8.4 (1.5)† −14.0 (1.5)† −7.7 (1.4)† −15.5 (1.5)† −6.8 (1.4)‡ −10.7 (1.5)†
*The adalimumab 40 mg Q2W treatment arm served as active reference for comparison with placebo. The study was not powered to test equivalence or non-inferiority of ixekizumab
versus adalimumab.
†p≤0.001 vs placebo.
‡p≤0.01 vs placebo.
§Data reported for patients with a baseline HAQ-DI score ≥0.35. The MCID for HAQ-DI is an improvement from baseline ≥0.35.
¶Post hoc analysis.
**Data are reported for patients with dactylitis, as qualitatively assessed by the investigator, at baseline and baseline LDI-B score >0.
††Data are reported for patients with enthesitis, as qualitatively assessed by the investigator, at baseline and baseline LEI score >0.
‡‡p<0.05 vs placebo.
§§p≤0.025 vs placebo.
¶¶Data are reported for patients with baseline psoriatic lesion(s) involving ≥3% BSA.
***Data are reported for patients with sPGA ≥3 at baseline.
†††Data are reported for patients with fingernail psoriasis, as qualitatively assessed by the investigator, at baseline.
‡‡‡Data are reported for patients with enthesitis, as qualitatively assessed by the investigator, at baseline.
§§§Data are reported for patients with psoriasis, as qualitatively assessed by the investigator, at baseline.
ACR20/50/70, 20/50/70% American College of Rheumatology response; BSA, body surface area; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Health
Assessment Questionnaire-Disability Index; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; LDI-B, Leeds Dactylitis Index-Basic; LEI, Leeds
Enthesitis Index; LS, least squares; MCID, minimal clinically important difference; NAPSI, Nail Psoriasis Severity Index; PASI 75/90/100, Psoriasis Area and Severity Index Improvement
Response for 75/90/100%; Q2W, every 2 weeks; SF-36 PCS, Short Form (36 Items) Health Survey Physical Component Score; sPGA, static Physician Global Assessment of psoriasis.
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body mass index (BMI) compared with the placebo group
(table 1), a Cochran-Armitage trend test within the adalimumab
group demonstrated no effect of weight or BMI on the ACR20
response at week 24 (data not shown). The ACR20 response at
12 weeks, tested as a secondary end point, was also signiﬁcantly
greater in patients randomised to IXEQ4W (57%) and
IXEQ2W (60.2%) versus placebo (31.1%) (p≤0.001). ACR20
response rates for both ixekizumab groups and the adalimumab
group were signiﬁcantly greater than the placebo group as early
as week 1 (p≤0.01), and the differences were maintained
throughout the 24-week period (p≤0.01). The treatment
responses on ixekizumab were signiﬁcantly greater than those
on placebo as early as week 4 for ACR50 and week 8 for
ACR70 and persisted through week 24 (p<0.05) (ﬁgure 1B, C).
Mean reductions in each component of the ACR core set are
presented in online supplementary ﬁgure S4 and table S1.
Mean reductions in the level of disease activity observed with
the DAS28-CRP at week 24 were −0.84 with placebo and
−1.96, −2.04 and −1.74 in the IXEQ4W, IXEQ2W and
adalimumab groups (all p≤0.001), respectively (table 2 and see
online supplementary ﬁgure S5A). At week 24, improvements
from baseline in physical function, measured by HAQ-DI, were
signiﬁcantly greater in patients receiving IXEQ4W (−0.44),
IXEQ2W (−0.50) and adalimumab (−0.37) than in those
receiving placebo (−0.18) (p≤0.01) (table 2 and see online
supplementary ﬁgure S4F). For patients with HAQ-DI ≥0.35 at
baseline, a greater percentage of patients achieved the minimal
clinically important difference in HAQ-DI (improvement ≥0.35
from baseline)27 at week 24 in the IXEQ4W (49.0%), IXEQ2W
(57.8%) and adalimumab (49.4%) groups compared with the
placebo group (26.1%) (p≤0.001) (table 2). The improvement
from baseline in Short Form (36 Items) Health Survey Physical
Component Score was also signiﬁcantly greater at week 24 for
patients receiving IXEQ4W (7.5), IXEQ2W (8.2) and adalimu-
mab (6.8) compared with those receiving placebo (2.9)
(p≤0.01) (table 2).
Progression of structural damage, measured by changes from
baseline in mTSS at week 24, was signiﬁcantly less in the
IXEQ4W (0.17), IXEQ2W (0.08) and adalimumab (0.10)
groups than in the placebo group (0.49) (p≤0.01) (table 3).
Signiﬁcantly greater percentages of patients in the ixekizumab
groups and adalimumab group at week 24 experienced no struc-
tural progression as deﬁned by thresholds of ≤0.5 or ≤0.95
compared with the placebo group (table 3).
For patients with dactylitis and LDI-B >0 at baseline, signiﬁ-
cantly greater improvements in mean LDI-B scores at week 24
(post hoc analysis) were observed for the IXEQ4W, IXEQ2W
and adalimumab groups compared with the placebo group
(p≤0.01) (table 2 and see online supplementary ﬁgure S5B),
and complete resolution of dactylitis symptoms (LDI-B=0) at
week 24 (post hoc analysis) occurred at a greater rate in the
IXEQ4W (80%), IXEQ2W (77%) and adalimumab (78%)
groups than in the placebo group (25%) (p≤0.001) (table 2 and
see online supplementary ﬁgure S6A). For patients with enthesi-
tis at baseline, the reduction in LEI score at week 12 was greater
only in the IXEQ2W group than in the placebo group
(p=0.038); the change did not reach the signiﬁcance threshold
(p<0.025) based on the multiplicity-controlled analysis. At
week 24, reductions in LEI score were numerically greater in
both ixekizumab groups than in the placebo group (IXEQ4W,
−1.3 p=0.151; IXEQ2W, −1.4 p=0.099; placebo, −0.8) but
did not meet statistical signiﬁcance (table 2 and see online
supplementary ﬁgure S5C). Among patients with LEI>0 at base-
line, complete resolution of enthesitis symptoms (LEI=0) at
week 24 (post hoc analysis) occurred at a greater rate with
IXEQ4W (43%) and IXEQ2W (39%) than with placebo (19%)
(p<0.05) (table 2 and see online supplementary ﬁgure S6B).
Among patients with psoriasis at baseline affecting ≥3% BSA,
a signiﬁcantly greater percentage of patients achieved PASI 75 at
week 12 for the IXEQ4W (75.3%), IXEQ2W (69.5%) and ada-
limumab (33.8%) groups compared with the placebo group
(7.5%) (p<0.001) (table 2 and ﬁgure 2A). Signiﬁcantly greater
PASI responses compared with placebo were observed as early
as week 4 for PASI 75 and PASI 90, and week 8 for PASI 100
(p≤0.01) (ﬁgure 2). For patients with nail involvement at base-
line, mean changes from baseline in the NAPSI score at week 24
were signiﬁcantly greater for the IXEQ4W (−14.0), IXEQ2W
(−15.5) and adalimumab (−10.7) groups than for the placebo
group (−2.4) (p≤0.001) (table 2). At week 24, a signiﬁcantly
greater percentage of patients achieved complete resolution of
nail psoriasis (NAPSI=0) in the IXEQ2W (36.5%) and adalimu-
mab (39.4%) groups compared with the placebo group (18.9%)
(p<0.025).
Figure 1 Time course of ACR responses. The percentages of patients
achieving ACR20 (A), ACR50 (B) and ACR70 (C) are shown. Patients
with inadequate responses to treatment at week 16 or missing data
were analysed as non-response up to week 24. aActive reference arm
for comparison with placebo. The study was not powered to test
equivalence or non-inferiority of ixekizumab versus adalimumab.
ACR20/50/70, 20/50/70% American College of Rheumatology response;
ADAQ2W, 40 mg adalimumab once every 2 weeks; IXEQ2W, 80 mg
ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every
4 weeks; PBO, placebo; Q2W, once every 2 weeks.
Mease PJ, et al. Ann Rheum Dis 2017;76:79–87. doi:10.1136/annrheumdis-2016-209709 83
Clinical and epidemiological research
Safety proﬁle
A greater percentage of patients receiving ixekizumab (66%)
and adalimumab (64%) reported at least one treatment-emer-
gent AE compared with patients receiving placebo (47.2%).
These were mostly mild or moderate, and the most common
were injection site reaction, injection site erythema and naso-
pharyngitis (table 4).
Across all groups, 10 patients (2.4%) discontinued because of
an AE. No deaths occurred. Injection site reactions were mostly
mild in intensity and were more frequent in the ixekizumab
groups than in the placebo group (see online supplementary
table S2). No serious AEs (SAEs) of injection site reactions were
reported, and four patients discontinued due to an AE of injec-
tion site reactions (two IXEQ2W, one adalimumab, one
placebo). Reductions in neutrophils from normal levels, meeting
the deﬁnition of National Cancer Institute Common
Terminology Criteria for Adverse Events of grade 1 (lower limit
of normal to 1500 cells/mm3) and grade 2 (<1500–1000 cells/
mm3) neutropenia,28 occurred in 6.2% and 4.8%, respectively,
of the patients treated with ixekizumab (data not shown). One
patient had grade 2 neutropenia on more than one assessment;
no infection onset occurred within 14 days of any report of
grade 2 neutropenia. There were no instances of grade 3
(<1000–500 cells/mm3) or higher neutropenia, major cerebro-
cardiovascular events (cardiovascular death, myocardial infarc-
tion stroke, etc), interstitial lung disease/Pneumocystis
pneumonia, Crohn’s disease or ulcerative colitis in the
ixekizumab-treated patients. Depression-related symptoms were
reported in three patients in the ixekizumab groups; none were
reported in the placebo group. One patient randomised to
IXEQ2W discontinued from the study because of worsening of
mild depression existing at baseline. No AEs of suicidal ideation
or suicide attempt were reported. AEs of infection were similar
in frequency between all treatment groups; the most commonly
reported infections in the combined ixekizumab groups were
nasopharyngitis, upper respiratory tract infection, bronchitis,
conjunctivitis, oral herpes and pharyngitis (see online
supplementary table S3). One patient treated with IXEQ2W
experienced herpes zoster involving the eyelid, which was classi-
ﬁed as a SAE. Four other SAEs of infection were gastroenteritis
(IXEQ4W), oesophageal candidiasis (IXEQ2W), cellulitis (adali-
mumab) and mycoplasma pneumonia (adalimumab). All SAEs
of infection resolved with treatment and did not lead to study
discontinuation. One case of oral candidiasis (mild) was
reported as an AE (IXEQ4W). There were no cases of invasive
fungal disease or clinically active or reactivated tuberculosis.
Mild or moderate hypersensitivity events, most commonly man-
ifesting as rash or urticaria, were reported in seven patients in
the ixekizumab groups; none were reported as serious. One
patient treated with IXEQ4W discontinued the study due to
rash. In the ixekizumab treatment groups, 11 patients had
treatment-emergent anti-ixekizumab antibodies, and none had
detectable neutralising antibodies; 72.7% (n=8/11) of these
patients achieved an ACR20 response at week 24.
Table 3 Effect on structural disease progression
Placebo IXEQ4W IXEQ2W Adalimumab 40 mg Q2W*
N=106 N=107 N=103 N=101
LS mean change from baseline mTSS (SE)† Week 16 0.36 (0.07) 0.13 (0.07)‡ 0.06 (0.07)§ 0.12 (0.08)‡
Week 24 0.49 (0.09) 0.17 (0.08)§ 0.08 (0.08)¶ 0.10 (0.09)¶
Percentage of patients with change in mTSS at week 24 ≤0 72.0 83.0 83.5 91.6¶
≤0.5 77.4 89.0** 94.8¶ 95.8¶
≤0.95 83.9 94.0‡ 96.9§ 95.8§
*The adalimumab 40 mg Q2W treatment arm served as active reference for comparison with placebo. The study was not powered to test equivalence or non-inferiority of ixekizumab
versus adalimumab.
†Higher mTSS scores indicate more articular damage. The mean change from baseline at week 24 was assessed with a statistical significance threshold of p<0.025 in a hierarchical
analysis; all other end points were assessed with a statistical significance threshold of p<0.05.
‡p≤0.025 vs placebo.
§p≤0.01 vs placebo.
¶p≤0.001 vs placebo.
**p<0.05 vs placebo.
IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; LS, least squares; mTSS, van der Heijde modified total Sharp score; Q2W, every 2 weeks.
Figure 2 Time course of PASI responses. The percentages of patients achieving PASI 75 (A), PASI 90 (B) and PASI 100 (C) are shown. PASI was
measured in patients with baseline psoriatic lesion(s) involving ≥3% body surface area. Patients with inadequate responses to treatment at week 16
or missing data were analysed as non-response up to week 24. aActive reference arm for comparison with placebo. The study was not powered to
test equivalence or non-inferiority of ixekizumab versus adalimumab. PASI 75/90/100, Psoriasis Area and Severity Index Improvement Response for
75/90/100%; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; Q2W, once every 2 weeks.
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DISCUSSION
In this phase III study, 80 mg of ixekizumab administered
every 2 weeks or 4 weeks after a starting dose of 160 mg sig-
niﬁcantly improved signs and symptoms, including enthesitis
and dactylitis, of PsA and patient-reported physical function-
ing, while also inhibiting bone destruction. Both ixekizumab
dose regimens signiﬁcantly reduced radiographic progression
of joint damage when compared with placebo. A rapid thera-
peutic response was apparent as early as 1 week after beginning
therapy. Moreover, nearly half of the patients with ≥3%
affected BSA who were treated with ixekizumab achieved
complete clearance of their psoriasis, a result consistent
with earlier studies of ixekizumab in patients with moderate-
to-severe psoriasis.29 30
A numerically greater proportion of patients receiving
IXEQ2W achieved, for many end points, greater efﬁcacy at
week 24 compared with IXEQ4W. However, a formal compari-
son of the two ixekizumab treatments was not prespeciﬁed in
the study design. Of note, the study was not intended to assess
the effects of the 160 mg starting dose.
Patients treated with adalimumab, the active reference group,
demonstrated signiﬁcant efﬁcacy compared with placebo across
disease activity, functional outcome and radiographic endpoints.
The inclusion of adalimumab, an active control, served as an
internal reference arm to assess the relative efﬁcacy of an
approved and established treatment compared with placebo in
the same study patient population as that for ixekizumab. The
positive efﬁcacy results for adalimumab further support the
Table 4 Safety overview
Placebo IXEQ4W IXEQ2W Adalimumab 40 mg Q2W*
(N=106) (N=107) (N=102) (N=101)
TEAE, n (%) 50 (47.2) 71 (66.4)† 67 (65.7)† 65 (64.4)‡
Mild 27 (25.5) 43 (40.2)§ 41 (40.2)§ 39 (38.6)
Moderate 21 (19.8) 24 (22.4) 21 (20.6) 25 (24.8)
Severe 2 (1.9) 4 (3.7) 5 (4.9) 1 (1.0)
Most frequent TEAEs¶, n (%)
Injection site reaction 0 13 (12.1)** 16 (15.7)** 2 (2.0)
Injection site erythema 0 7 (6.5)‡ 13 (12.7)** 2 (2.0)
Nasopharyngitis 5 (4.7) 7 (6.5) 3 (2.9) 7 (6.9)
Headache 1 (0.9) 4 (3.7) 4 (3.9) 3 (3.0)
Upper respiratory tract infection 7 (6.6) 5 (4.7) 3 (2.9) 5 (5.0)
ALT increased 0 3 (2.8) 4 (3.9) 3 (3.0)
Diarrhoea 3 (2.8) 2 (1.9) 5 (4.9) 3 (3.0)
Muscle spasms 1 (0.9) 3 (2.8) 4 (3.9) 1 (1.0)
Bronchitis 3 (2.8) 3 (2.8) 3 (2.9) 4 (4.0)
AST increased 0 2 (1.9) 3 (2.9) 2 (2.0)
Nausea 2 (1.9) 0 5 (4.9) 4 (4.0)
Psoriatic arthropathy 1 (0.9) 3 (2.8) 2 (2.0) 3 (3.0)
Back pain 0 2 (1.9) 2 (2.0) 3 (3.0)
Serious adverse events, n (%) 2 (1.9) 6 (5.6) 3 (2.9) 5 (5.0)
Serious infection, n (%) 0 1 (0.9) 2 (2.0) 2 (2.0)
Discontinued due to AE, n (%) 2 (1.9) 2 (1.9) 4 (3.9) 2 (2.0)
AEs of special interest††, n (%) 36 (34.0) 52 (48.6)§ 56 (54.9)† 45 (44.6)
Infection 27 (25.5) 30 (28.0) 24 (23.5) 26 (25.7)
Any candida infection 0 1 (0.9) 1 (1.0) 0
Active or reactivated tuberculosis 0 0 0 0
Injection site reactions 5 (4.7) 26 (24.3)** 27 (26.5)** 6 (5.9)
Hepatic event 7 (6.6) 5 (4.7) 9 (8.8) 13 (12.9)
Allergic reaction/hypersensitivity 3 (2.8) 2 (1.9) 5 (4.9) 5 (5.0)
Cytopenia (all types) 6 (5.7) 1 (0.9) 4 (3.9) 4 (4.0)
Neutropenia 0 0 1 (1.0) 0
Depression 0 2 (1.9) 1 (1.0) 1 (1.0)
Cerebrocardiovascular event 0 0 0 3 (3.0)
Malignancy 1 (0.9) 0 0 1 (1.0)
*The adalimumab 40 mg Q2W treatment arm served as active reference for comparison with placebo. The study was not powered to test equivalence or non-inferiority of ixekizumab
versus adalimumab.
†p≤0.01 vs placebo.
‡p≤0.025 vs placebo.
§p<0.05 vs placebo.
¶Adverse events are listed according to the preferred term in MedDRA, V.17.1, and are events that occurred in ≥2.0% of the patients in the combined ixekizumab group.
**p≤0.001 vs placebo.
††Reported as adverse events and coded using MedDRA, V.17.1. Groups of adverse events of special interest are shown; adverse events of special interest not reported in any group
included pneumocystis pneumonia, Crohn’s disease/ulcerative colitis and interstitial lung disease.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks;
MedDRA, Medical Dictionary for Regulatory Activities; Q2W, once every 2 weeks; TEAE, treatment-emergent adverse event.
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ability of SPIRIT-P1 to distinguish active treatments from
placebo.
Within this manuscript, improvement in LDI-B is presented
for two different baseline patient populations (see online
supplementary table S4): (1) presence of dactylitis, based on a
qualitative assessment conducted by the investigator (prespeci-
ﬁed) or (2) presence of dactylitis, based on a qualitative assess-
ment conducted by the investigator, and a baseline LDI-B score
>0 (post hoc). Both assessments demonstrate a signiﬁcant
improvement in dactylitis with ixekizumab or adalimumab
treatment versus placebo. However, the latter (post hoc) ana-
lysis uses a baseline population identiﬁed by applying a more
objective measure (ie, based on a measurement of digit circum-
ference and digit tenderness), which is intended to provide a
clinically meaningful, yet more rigorous, estimation of the
treatment effect.
The efﬁcacy ﬁndings further highlight the role of IL-17A in
the pathogenesis of PsA.12 13 31
The safety proﬁle of ixekizumab was consistent with ﬁndings
reported aligned with the safety proﬁle in moderate-to-severe
plaque psoriasis.29 30 Other than ﬁndings related to mild-to-
moderate, transient injection site reactions, most AEs occurred
at similar rates to those observed with placebo. IL-17A can
regulate neutrophil homoeostasis via several mediators of neu-
trophil production, trafﬁcking and function, such as granulo-
cyte colony-stimulating factor, growth-related oncogene-α and
IL-8. Furthermore, IL-17A is integrally involved in host mucosal
defences against Candida albicans,32–34 which may contribute to
the increased number of cases of candidiasis associated with
IL-17A inhibition,12 13 30 including the two reported in the
current study. Treatment-emergent neutropenia was of grade 1
or 2. Observed infections occurred at similar rates in active
treatment and placebo groups. No obvious correlation between
ixekizumab dosing frequency and AEs was observed in this
study.
The 24-week placebo controlled study duration was based on
existing data and ethical considerations to minimise the duration
of exposure to placebo treatment. An extension period of up to
3 years will permit longer-term safety and efﬁcacy evaluations.
Given that the current study was restricted to patients who were
naive to biologic therapy, the results cannot be generalised to
treatment of patients with a history of failed therapy or loss of
efﬁcacy to therapy or intolerance to anti-tumor necrosis factor
(TNF) agents. Evaluation of ixekizumab in patients with PsA
with previous experience with biologic therapy is currently
under investigation in the SPIRIT-P2 clinical trial
(NCT02349295; EudraCT 2011-002328-42).
In conclusion, 24 weeks of treatment with ixekizumab
improved the key clinical domains of PsA. The safety ﬁnd-
ings were consistent with the current understanding of
IL-17A inhibition and the clinical proﬁle observed in previ-
ous ixekizumab studies in patients with moderate-to-severe
psoriasis. The present ﬁndings support the view that IL-17A
is a key cytokine in the pathogenesis of PsA and an import-
ant therapeutic target.
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